Background: Clinical pharmacists play a role in limiting the disadvantages of pharmacotherapy for patients by detecting and resolving drug-related problems (DRPs) through medication reviews. Although their contributions to patient care have been analyzed and understood in various countries, the role of Japanese clinical pharmacists in this context remains to be clearly elucidated. Thus, in this study, we aimed to elucidate the detection of DRPs by clinical pharmacists and determine the potential impact of pharmacist interventions in Japan.
Methods: This study was conducted in a 273-bed hospital and targeted hospitalized patients over a period of 6 months. DRPs detected by clinical pharmacists during the study period were investigated and classified into 10 types. Furthermore, medications were categorized according to the Anatomical Therapeutic Chemical classification. A review committee consisting of two pharmacists independently reviewed the pharmacist interventions on a six-point scale (extremely significant, very significant, significant, somewhat significant, no significance, adverse significance) according to the potential impact on patient care.
Results: During the study period, 1711 patients (mean age: 71.2 years, 54.1% male) were included, and 2149 DRPs were detected (1.26 DRPs/patient). Pharmacists intervened in all the DRPs detected. The most common DRP was supratherapeutic dosage (19.3%), followed by untreated indication (18.1%). The most common medication classification causing DRPs was "Antiinfectives for Systemic Use" (25.1%), followed by "Alimentary Tract and Metabolism" (19.9%). Most of the pharmacist interventions (99.6%) were rated "somewhat significant" or more significant, of which 1.1% were rated "extremely significant," and none were rated as "adverse significance."
Conclusions: Our results show that in Japan, as in other countries, clinical pharmacists detect and resolve DRPs in hospitalized patients through medication review. Our findings also show that clinical pharmacists have a positive impact on patient care and suggest the need for their involvement.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8647485 | PMC |
http://dx.doi.org/10.1186/s40780-021-00232-9 | DOI Listing |
J Viral Hepat
February 2025
Monash Addiction Research Centre, Eastern Health Clinical School, Monash University, Melbourne, Victoria, Australia.
The World Health Organisation (WHO) has set goals to eliminate hepatitis C (HCV) as a global health threat by 2030. To meet this goal, Australia must increase testing and diagnosis, including expanding access to care through community pharmacists. This study aims to explore community pharmacists' preparedness to discuss and offer HCV testing and treatment.
View Article and Find Full Text PDFJ Adv Nurs
January 2025
School of Nursing and Midwifery, Centre for Quality and Patient Safety Research, Institute for Health Transformation, Deakin University, Geelong, Victoria, Australia.
Aim(s): To identify and synthesise available evidence about regular medication management processes, from preadmission to discharge from hospital, in patients with cancer undergoing surgery.
Design: Mixed-methods systematic review.
Methods: Studies published from inception of each database until February 2023 were screened, utilising four main search concepts.
Front Med (Lausanne)
January 2025
Department of Pharmacy Practice, College of Clinical Pharmacy, King Faisal University, Al-Ahsa, Saudi Arabia.
Background: Community pharmacists are most accessible to patients. Hence, they have a crucial role in ensuring drug safety by detecting and reporting adverse drug reactions (ADRs). However, there may be gaps in their knowledge of ADR reporting systems and barriers they face in reporting.
View Article and Find Full Text PDFCan J Kidney Health Dis
January 2025
Faculty of Health, College of Pharmacy, Dalhousie University, Halifax, NS, Canada.
Background: Diabetes is the leading cause of kidney disease and contributes to 38% of kidney failure requiring dialysis. A gap in detection and management of type 2 diabetes (T2D) in chronic kidney disease (CKD) exists in primary care. Community pharmacists are positioned to support those not able to access kidney care through traditional pathways.
View Article and Find Full Text PDFWomen Health
January 2025
College of Pharmacy, QU Health Sector, Qatar University, Doha, Qatar.
In Qatar, hormonal contraceptives are available over the counter in community pharmacies. However, improper use, particularly by women with specific health conditions, can result in adverse events. Community pharmacists (CPs) play a role in counseling women and assessing eligibility for contraceptives.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!